Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
Part of paid clinical trials in New York, New York.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT00087282
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- alvocidib — DRUG
- irinotecan hydrochloride — DRUG
Study Details
RATIONALE: Drugs used in chemotherapy, such as irinotecan and flavopiridol, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving irinotecan together with flavopiridol works in treating patients with advanced liver cancer.
Key Dates
- Start date
- Jun 30, 2004
- Status verified
- May 2005
- Completion
- Jul 31, 2006
Study Design
- Primary purpose
- TREATMENT
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | - |
Find similar trials in New York, NY
By condition
By specialty
By research site
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- National Liver Cancer Screening TrialPHASE4 · Recruiting · University of Texas Southwestern Medical Center · Los Angeles, California
- Brodalumab in the Treatment of Immune-Related Adverse EventsPHASE1 · Recruiting · Brian Henick, MD · New York, New York
- HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver CancerRecruiting · Montefiore Medical Center · The Bronx, New York